glJMed2010;363:1875–6BID=每日两次;RR=相对危险度;RRR=相对危险降幅;Sup=有效性出血性卒中(事件数量)n:601560766022达比加群?110mgBID达比加群?150mgBID华法林01020304050140.12%120.10%450.38%RR0.31(95%CI:0.17–0.56)P<0.001(Sup)RR0.26(95%CI:0.14–0.49)P<0.001(Sup)69%74%exilateisinclinicaldevelopmentandnotlicensedforclinicaluseinstrokepreventionforpatientswithatrialfibrillationinChinap(sup.)<0.001forPradaxa®150mgbidvs.华法林;p(sup.)=n.s.forPradaxa®110mgbidvs.华法林每10万例患者中,达比加群150mg比华法林可多预防570例卒中事件RE-LY研究:达比加群150mg较华法林?显著降低血管性死亡的风险15%BID=每日两次;RR=相对危险度;Sup=优效性ConnollySJ,etal.NEnglJMed.2009;361:1139–51.ConnollySJ,etal.NEnglJMed.2010;363:1875–6.血管性死亡(100患者-年)n:289/6015274/6076317/6022达比加群?110mgBID达比加群?150mgBID华法林00.51.01.52.02.43%2.28%2.69%RR0.90(95%CI:0.77–1.06)P=0.21(Sup)RR0.85(95%CI:0.72–0.99)P=0.04(Sup)15%2.53.0**每10万例患者中,达比加群150mg比华法林可多预防490例死亡
全文预览
